Lykos tried to turn a psychedelic therapy born in nonprofit research into a prescription treatment for PTSD. Its FDA setback showed how much more a promising result must prove before it becomes medicine.
PsyMed Ventures started with a podcast and a narrow question about psychedelic medicine. Six years later, its portfolio makes a broader wager: that the next important health companies will treat the brain as biology, data and lived experience at once.
Delphi treats a mushroom farm, a digital clinic and a psychedelic drug developer as pieces of the same puzzle: how to finance a healthier relationship between people and the planet.
Journey Clinical is a New York-based healthtech company that operates a collaborative-care platform enabling licensed psychotherapists to offer Ketamine-Assisted Psychotherapy (KAP) inside their own private practices. Its in-house medical team handles patient eligibility, ketamine prescriptions, and ongoing medical monitoring, while therapists deliver the preparation, dosing, and integration sessions. The model expands safe, legal access to psychedelic-assisted care for patients with depression, anxiety, PTSD, and other conditions, and has grown to a network of over 2,500 trained providers.
Wonder Sciences is a Los Angeles-based mental health and research company reengineering psychiatric care through psychedelic medicine, clinical research, and AI. Best known for its consumer brand Wondermed - an at-home, low-dose ketamine-assisted telehealth protocol for anxiety and depression - the company is building an AI-native clinical operating system that fuses medication, therapy, and behavioral data into actionable insights. Founded by Ryan Magnussen in 2022, it raised roughly $4.6M-$5.6M in seed funding from investors including Aubrey Marcus and James Foster.